Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.59 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19614958 | 1.00 | GRIN2B (0.59) | GRIN2BGRIN2CHSD11B1USP2CYP3A4 | |
| SCHEMBL19614956 | 1.00 | GRIN2B (0.59) | GRIN2BGRIN2CHSD11B1USP2CYP3A4 | |
| SCHEMBL19628502 | 1.00 | GRIN2B (0.59) | GRIN2BGRIN2CHSD11B1USP2CYP3A4 | |
| SCHEMBL19614952 | 1.00 | GRIN2B (0.59) | GRIN2BGRIN2CHSD11B1USP2CYP3A4 | |
| SCHEMBL19614959 | 1.00 | GRIN2B (0.59) | GRIN2BGRIN2CHSD11B1USP2CYP3A4 | |
| Fumaric Acid SCHEMBL19616602 | 0.94 | GRIN2B (0.54) | GRIN2BGRIN2CHSD11B1 | |
| SCHEMBL19614954 | 0.93 | GRIN2B (0.59) | GRIN2BGRIN2CHSD11B1LMNACA12 | |
| SCHEMBL19614951 | 0.93 | GRIN2B (0.59) | GRIN2BGRIN2CHSD11B1LMNACA12 | |
| SCHEMBL19614947 | 0.93 | GRIN2B (0.59) | GRIN2BGRIN2CHSD11B1LMNACA12 | |
| SCHEMBL19614949 | 0.93 | GRIN2B (0.59) | GRIN2BGRIN2CHSD11B1LMNACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458458-B1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2020-11-04 | — | — | EP | disclosed |
| US-10196401-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180093994-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-04-05 | — | — | US | disclosed |
| US-9932347-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170334922-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093994-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885HSD11B1 2229/4885 |
| US-10196401-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885HSD11B1 2229/4885 |
| US-20170334922-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885HSD11B1 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.